← Back to Directory

iBio, Inc. (IBIO) - Latest Market Data

Track the most recent price, market cap, volume, and performance data for iBio, Inc. (IBIO).

Download StockRank on Google Play Download StockRank on the App Store

Equity Details

Price & Market Data

Price: $1.66

Daily Change: -$0.0034 / 0.21%

Daily Range: $1.56 - $1.70

Market Cap: $58,191,132

Daily Volume: 396,731

About iBio, Inc. (IBIO)

Dive deep into iBio, Inc. (IBIO)'s market performance. Current price: 1.66, daily change: -$0.0034 / 0.21%. Market cap: 58,191,132. All key performance metrics are available, from 1-week to 1-year and YTD.

Company Details

Employees: 20

Sector: Health technology

Industry: Pharmaceuticals: other

Country: United States

Details

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2–expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Selected stocks

Pony AI Inc. (PONY)

Chemours Company (The) (CC)

OneMedNet Corp (ONMD)

Apollo Commercial Real Estate Finance, Inc (ARI)

Hoyne Bancorp, Inc. (HYNE)